News, infos and good to know WKN: A2QQ2E ISIN: US45256X1037 Kürzel: IBRX Forum: Aktien User: Lirumlarum1

ImmunityBio, Inc. @ImmunityBio ICYMI: See how N-803 is being used to enhance the function of #NKcells in controlling the burden of infection from #HIV in a study led by @umnmedschool https://twitter.com/immunitybio/status/1760073220584026271?s=46

Blair William & Co. IL Acquires 108,431 Shares of ImmunityBio, Inc. (NASDAQ:IBRX) https://www.defenseworld.net/2024/02/21/blair-william-co-il-acquires-108431-shares-of-immunitybio-inc-nasdaqibrx.html

ImmunityBio: Buy Low Now Vs. Buy High Later https://seekingalpha.com/article/4669321-immunitybio-buy-low-now-vs-buy-high-later

ImmunityBio Quality-of-Life Study in BCG-Unresponsive Bladder Cancer Trial Indicates Improved Physical Function in the 71% Complete Responders Suggesting a Favorable Risk-Benefit Ratio for N-803 Plus BCG https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-quality-life-study-bcg-unresponsive-bladder-cancer?field_nir_news_date_value[min]=

ImmunityBio Awarded Seminal Patent on Natural Killer Cells https://immunitybio.com/immunitybio-awarded-seminal-patent-on-natural-killer-cells/

https://nant.wd5.myworkdayjobs.com/ImmunityBio

ImmunityBio Announces $320 Million Investment by Oberland Capital, with $210 Million Funded at Closing, Bringing Total Financing in 2023 to $850 Million https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-announces-320-million-investment-oberland-capital?field_nir_news_date_value[min]=

https://seekingalpha.com/article/4659148-immunitybio-approval-likely-priced-in-yielding-mostly-risk-for-would-be-buyers?source=content_type%3Areact%7Csection%3AAll%7Csection_asset%3AAnalysis%7Cfirst_level_url%3Asymbol%7Cbutton%3ATitle%7Clock_status%3ANo%7Cline%3A1

https://www.marketscreener.com/quote/stock/IMMUNITYBIO-INC-23160241/news/ImmunityBio-Inc-NasdaqGS-IBRX-added-to-S-P-Biotechnology-Select-Industry-Index-45586244/?utm_source=copy&utm_medium=social&utm_campaign=share

Einfach anmelden und den Webcast hören, ist wirklich interessant. Die Zuversicht bezüglich der Zulassung scheint doch sehr groß zu sein.

ImmunityBio, Inc. @ImmunityBio Folgen Today, during the 35th Annual @Piper_Sandler Healthcare Conference, we had the opportunity to participate in a fireside discussion with Director & Sr. Research Analyst, Joe Catanzaro, Ph.D. Replay of the presentation: https://bit.ly/40OoDnl https://twitter.com/immunitybio/status/1730377169581265291?s=46